公开(公告)号：EP0917469A1

公开(公告)日：1999-05-26

申请号：EP97922438.0

申请日：1997-04-18

申请人： ZymoGenetics, Inc. ,  University of Washington

发明人： DURNAM, Diane, M. ,  KUIJPER, Joseph, L. ,  WEIGLE, David, S. ,  LIU, Chung, C.

IPC分类号： A61K38 ,  A61K31 ,  A61P19 ,  A61P43 ,  C12N5 ,  A61K35

CPC分类号： C12N5/0654 ,  A61K35/12 ,  A61K38/2264 ,  C12N2501/355 ,  C12N2502/076

摘要： Methods for inducing bone formation using ob protein are disclosed. The methods can be used for treating osteoporosis, repairing fractures, dental defects, resectioning due to oncogenesis and elongation of the growth plate/long bone. In addition, the methods can be used for ex vivo therapy and reinfused into a mammal.

公开(公告)号：EP0874898A1

公开(公告)日：1998-11-04

申请号：EP96940607.0

申请日：1996-11-26

申请人： ZymoGenetics, Inc. ,  PPL Therapeutics

发明人： GARNER, Ian ,  COTTINGHAM, Ian ,  TEMPERLEY, Simon, M. ,  FOSTER, Donald, C. ,  SPRECHER, Cindy, A. ,  PRUNKARD, Donna, E.

IPC分类号： A01K67 ,  C12N9 ,  C12N15

摘要： Methods for producting protein C in transgenic non-human mammals are disclosed. The protein C is modified at the two-chain cleavage site between the light and heavy chains of protein C from Lys-Arg to R1-R2-R3-R4 where R1 through R4 are individually Arg or Lys. DNA segments encoding modified protein C are introduced into the germ line of a non-human mammal, and the mammal or its female progeny produces milk containing protein C expressed from the introduced DNA segments. The protein C expressed from the introduced DNA segments has anticoagulant activity when activated. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous protein C are also disclosed.

公开(公告)号：EP0832209A1

公开(公告)日：1998-04-01

申请号：EP96918107.0

申请日：1996-06-04

申请人： ZymoGenetics, Inc.

发明人： LOK, Si

IPC分类号： C12N15 ,  C12N5 ,  C12P21 ,  C12Q1

CPC分类号： C12N15/1051 ,  C07K2319/02 ,  C07K2319/32 ,  C07K2319/90 ,  C12N15/625 ,  C12Q1/6858

摘要： Expression vectors and methods for cloning amino-terminal signal sequences are disclosed. These vectors and methods are useful tools for selecting, expressing and isolating previously unknown signal sequences. In turn, an orphan signal sequence can be used to clone, identify and isolate the corresponding orphan proteins that the orphan signal sequence directs to the surface of a cell. Using these expression vectors and methods, an orphan protein can be cloned in the absence of a functional assay that detects such protein.

公开(公告)号：EP0506821B1

公开(公告)日：1998-02-04

申请号：EP91901991.9

申请日：1990-12-28

申请人： ZYMOGENETICS, INC.

发明人： FOSTER, Donald, C. ,  HOLLY, Richard, D.

IPC分类号： C12P21/02 ,  C12P15/00 ,  C12N9/64 ,  C07H15/12

CPC分类号： C12N9/6464 ,  C07K2319/00 ,  C12N9/60 ,  C12Y304/21069

摘要： Human protein C molecules are modified to provide increased resistance to inactivation by human plasma factors while retaining substantially the biological activity of human protein C. The modifications are generally to the heavy chain of protein C, which chain may be substituted with a protein C heavy chain of non-human origin, such as bovine, yielding a chimeric protein C molecule. The human protein C heavy chain may also be modified to be human-like, in that at least one amino acid from a non-human sequence may be substituted for the corresponding residue(s) of the human sequence, thereby allowing the molecule to retain substantially human characteristics yet having increased resistance to inactivation. Also included are methods for producing the modified protein C molecules and pharmaceutical compositions thereof. The modified molecules, having an increased half-life in human plasma, are particularly useful for treating coagulation-related disorders, such as protein C deficiency or thrombosis, or for promoting fibrinolysis in a patient.

公开(公告)号：EP0808351A2

公开(公告)日：1997-11-26

申请号：EP96905309.0

申请日：1996-02-02

申请人： ZymoGenetics, Inc.

发明人： SPRECHER, Cindy, A.

IPC分类号： C12N15 ,  A61K35 ,  A61K38 ,  C07K1 ,  C07K14 ,  C12N5 ,  C12P21 ,  C12R1

CPC分类号： C07K14/8121

摘要： Cytoplasmic Antiproteinase-2 and Cytoplasmic Antiproteinase-3 nucleic acids and serine protease inhibitor proteins encoded thereby are useful in the purification of proteins and in the treatment of inflammatory diseases and diseases involving apoptosis.

公开(公告)号：EP0804554A1

公开(公告)日：1997-11-05

申请号：EP95933075.0

申请日：1995-09-11

申请人： ZymoGenetics, Inc.

发明人： MOORE, Emma, E. ,  MACKAY, Vivian, L.

IPC分类号： C12N15 ,  C12N5

CPC分类号： C12N5/0654 ,  C12N5/0639 ,  C12N5/0643 ,  C12N2501/392 ,  C12N2503/02 ,  C12N2510/04 ,  C12N2517/02

摘要： Cell lines have been prepared from growth suppressor gene deficient animals. The cells include immortalized precursor cells and differentiated cells such as osteoclast precursors, osteoblast precursors, megakaryocytes, osteoclasts, osteoblasts, pancreatic α-cells, pancreatic β-cells, pancreatic δ-cells, adipocytes, macrophages, chondrocytes, dendritic cells and hepatocytes. The cells are useful for constructing cDNA and protein libraries, screening agonists and antagonists of compounds and factors that affect metabolic pathways of specific cells and generating cell-specific antibodies.

公开(公告)号：EP0789759A1

公开(公告)日：1997-08-20

申请号：EP95938944.0

申请日：1995-10-24

申请人： ZymoGenetics, Inc. ,  NOVO NORDISK A/S

发明人： BERKNER, Kathleen L. ,  PETERSEN, Lars Christian ,  HART, Charles E. ,  HEDNER, Ulla ,  BREGENGAARD, Claus

IPC分类号： C12N15 ,  A61K38 ,  A61P7 ,  A61P9 ,  A61P43 ,  C12N9

CPC分类号： A61K38/166 ,  A61K38/49 ,  C12N9/6437 ,  C12Y304/21021 ,  Y10S514/822 ,  A61K2300/00

摘要： The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.

公开(公告)号：EP0688215A1

公开(公告)日：1995-12-27

申请号：EP94911467.0

申请日：1994-03-07

申请人： ZYMOGENETICS, INC.

发明人： PIGGOTT, James, R.

IPC分类号： C07D311 ,  A61K31 ,  A61P43

CPC分类号： A61K31/35 ,  A61K31/40

摘要： Methods and pharmaceutical compositions for the treatment of dermatitis are disclosed. 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments, including oral and topical medicaments, which are administered to a patient suffering from dermatitis. The methods and compositions are particularly useful in the treatment of conditions characterized by hyperproliferation of keratinocytes, such as psoriasis.

公开(公告)号：EP0686044A1

公开(公告)日：1995-12-13

申请号：EP94909627.0

申请日：1994-02-17

申请人： ZYMOGENETICS, INC. ,  THE UNIVERSITY OF WASHINGTON

发明人： HART, Charles E. ,  KENAGY, Richard D. ,  CLOWES, Alexander W.

IPC分类号： C12N15 ,  A61K31 ,  A61K39 ,  A61P7 ,  A61P9 ,  A61P43 ,  C07K16 ,  C12P21 ,  A61K38 ,  C12R1

CPC分类号： C07K16/2863 ,  A61K38/00 ,  A61K39/395 ,  C07K2317/24 ,  C07K2319/30 ,  C07K2319/32 ,  A61K2300/00

摘要： Methods of inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal an anti-PDGF receptor antibody, such as an anti-PDGF-alpha receptor antibody or an anti-PDGF-beta receptor antibody. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft.

公开(公告)号：EP0677062A1

公开(公告)日：1995-10-18

申请号：EP94905569.0

申请日：1993-12-30

申请人： ZYMOGENETICS, INC. ,  THE UNIVERSITY OF WASHINGTON

发明人： LABROO, Virender ,  SASAKI, Tomikazu

IPC分类号： A61K38 ,  A61P3 ,  C07K14

CPC分类号： C07K14/57527 ,  A61K38/00 ,  C07K14/585

摘要： Derivatized calcitonin molecules, pharmaceutical compositions comprising derivatized calcitonins, and methods of reducing serum calcium in a patient using the derivatized calcitonins are disclosed. The molecules are characterized by a derivatized amino terminus formed by combining a calcitonin with a cyclic, polycyclic or heterocyclic moiety. Multimeric forms of the molecules are also disclosed.